economictimes.indiatimes.com ·
Pregabalin Moved to Schedule H1 as Centre Cracks Down on Drug Misuse
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedIndia-specific regulatory tightening on pregabalin, an anticonvulsant and nerve pain medication. The reclassification to Schedule H1 imposes stricter control and monitoring on its sale and distribution, increasing compliance costs for pharmaceutical companies and potentially reducing volume for unapproved channels. Impact is limited to India's pharmaceutical sector, with no direct global commodity or supply chain disruption.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Pregabalin moved to Schedule H1 of Drugs Rules, 1945 by Union health ministry.
- Regulation due to potential misuse, especially among youth.
- Punjab FDA flagged severe health consequences and widespread addiction.
- Multiple seizures of illegally stocked pregabalin reported.
Pregabalin sales volumes may decline 3-5% over 2-4 weeks as prescription scrutiny increases.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHmid
- PHARMA_BIOTECHshort